Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

MOBILITY METABOLISM & WELLNESS, P.C.

NPI: 1063719425 · MOBILE, AL 36609 · Pain Medicine (Physical Medicine & Rehabilitation) Physician · NPI assigned 02/22/2011

$1.35M
Total Medicaid Paid
36,866
Total Claims
29,963
Beneficiaries
23
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialCRUMB, JAMES (PRESIDENT)
NPI Enumeration Date02/22/2011

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 5,913 $247K
2019 5,014 $270K
2020 3,490 $197K
2021 5,492 $216K
2022 5,801 $181K
2023 4,395 $136K
2024 6,761 $107K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 4,908 4,283 $656K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 7,271 6,335 $328K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 8,758 7,070 $93K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1,018 875 $73K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 2,443 1,239 $53K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 547 503 $43K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,866 690 $31K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 1,120 1,088 $25K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 180 173 $11K
36415 Collection of venous blood by venipuncture 6,023 5,038 $8K
80299 636 630 $7K
80061 Lipid panel 309 301 $4K
80053 Comprehensive metabolic panel 314 306 $4K
84403 116 116 $3K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 76 74 $2K
83735 314 306 $2K
82550 306 298 $2K
95911 13 13 $2K
80198 163 151 $2K
84550 309 301 $2K
95886 15 15 $2K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 77 75 $2K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 84 83 $820.00